tetano
Editor, Senior Moderator
Antiviral Res
. 2022 Jan 28;105254.
doi: 10.1016/j.antiviral.2022.105254. Online ahead of print.
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis
Jianyuan Zhao[SUP] 1 [/SUP], Qian Liu[SUP] 2 [/SUP], Dongrong Yi[SUP] 3 [/SUP], Quanjie Li[SUP] 3 [/SUP], SaiSai Guo[SUP] 3 [/SUP], Ling Ma[SUP] 3 [/SUP], Yongxin Zhang[SUP] 3 [/SUP], Dongxin Dong[SUP] 2 [/SUP], Fei Guo[SUP] 4 [/SUP], Zhenlong Liu[SUP] 5 [/SUP], Tao Wei[SUP] 6 [/SUP], Xiaoyu Li[SUP] 7 [/SUP], Shan Cen[SUP] 8 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid global emergence of SARS-CoV-2 highlights the importance and urgency for potential drugs to control the pandemic. The functional importance of RNA-dependent RNA polymerase (RdRp) in the viral life cycle, combined with structural conservation and absence of closely related homologs in humans, makes it an attractive target for designing antiviral drugs. Nucleos(t)ide analogs (NAs) are still the most promising broad-spectrum class of viral RdRp inhibitors. In this study, using our previously developed cell-based SARS-CoV-2 RdRp report system, we screened 134 compounds in the Selleckchemicals NAs library. Four candidate compounds, Fludarabine Phosphate, Fludarabine, 6-Thio-20-Deoxyguanosine (6-Thio-dG), and 5-Iodotubercidin, exhibit remarkable potency in inhibiting SARS-CoV-2 RdRp. Among these four compounds, 5-Iodotubercidin exhibited the strongest inhibition upon SARS-CoV-2 RdRp, and was resistant to viral exoribonuclease activity, thus presenting the best antiviral activity against coronavirus from a different genus. Further study showed that the RdRp inhibitory activity of 5-Iodotubercidin is closely related to its capacity to inhibit adenosine kinase (ADK).
Keywords: COVID-19; Nucleotide analogues; RdRp inhibitors; SARS-CoV-2.
. 2022 Jan 28;105254.
doi: 10.1016/j.antiviral.2022.105254. Online ahead of print.
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis
Jianyuan Zhao[SUP] 1 [/SUP], Qian Liu[SUP] 2 [/SUP], Dongrong Yi[SUP] 3 [/SUP], Quanjie Li[SUP] 3 [/SUP], SaiSai Guo[SUP] 3 [/SUP], Ling Ma[SUP] 3 [/SUP], Yongxin Zhang[SUP] 3 [/SUP], Dongxin Dong[SUP] 2 [/SUP], Fei Guo[SUP] 4 [/SUP], Zhenlong Liu[SUP] 5 [/SUP], Tao Wei[SUP] 6 [/SUP], Xiaoyu Li[SUP] 7 [/SUP], Shan Cen[SUP] 8 [/SUP]
Affiliations
- PMID: 35101534
- DOI: 10.1016/j.antiviral.2022.105254
Abstract
Coronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid global emergence of SARS-CoV-2 highlights the importance and urgency for potential drugs to control the pandemic. The functional importance of RNA-dependent RNA polymerase (RdRp) in the viral life cycle, combined with structural conservation and absence of closely related homologs in humans, makes it an attractive target for designing antiviral drugs. Nucleos(t)ide analogs (NAs) are still the most promising broad-spectrum class of viral RdRp inhibitors. In this study, using our previously developed cell-based SARS-CoV-2 RdRp report system, we screened 134 compounds in the Selleckchemicals NAs library. Four candidate compounds, Fludarabine Phosphate, Fludarabine, 6-Thio-20-Deoxyguanosine (6-Thio-dG), and 5-Iodotubercidin, exhibit remarkable potency in inhibiting SARS-CoV-2 RdRp. Among these four compounds, 5-Iodotubercidin exhibited the strongest inhibition upon SARS-CoV-2 RdRp, and was resistant to viral exoribonuclease activity, thus presenting the best antiviral activity against coronavirus from a different genus. Further study showed that the RdRp inhibitory activity of 5-Iodotubercidin is closely related to its capacity to inhibit adenosine kinase (ADK).
Keywords: COVID-19; Nucleotide analogues; RdRp inhibitors; SARS-CoV-2.